A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Clinical trial NCT01421667 · COMPLETED

Trial details

NCT number: NCT01421667
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin Lymphoma, T-Cell

Start date: 2011-08-01
Primary completion: 2015-06-01
Enrollment: 176

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.